Neuraura’s 2019 investor deck focuses on the technical superiority of its micro-fabricated neuro sensors, which are 350x smaller than legacy 6mm electrodes. The company positions itself as a critical infrastructure provider for the neuromodulation market, aiming to displace outdated sensor technology in brain implants. Their commercialization strategy is split between selling research tools to institutions like Harvard and Calgary, and licensing technology to giants like Medtronic and Boston Scientific. While the deck excels at demonstrating technical validation—citing 100% seizure detection…
Key takeaways
- Neuraura claims its sensors are 350x smaller than legacy 6mm electrodes, measuring just 17 micrometers (Slide 3).
- The technology offers 20x spatial resolution and 3x signal resolution compared to current standards (Slide 3).
- The company has achieved 100% seizure detection in animal trials and has 4 patents in process (Slide 3).
- Existing research collaborators include Harvard Medical School, UC San Diego, and the University of Melbourne (Slide 4).
- The go-to-market strategy involves selling research tools to KOLs to generate publications before moving to channel partners (Slide 4).
- Neuraura targets licensing agreements with major medical device firms including Medtronic, Boston Scientific, and Abbott (Slide 5).
- The core team is led by two PhDs specializing in neuro-engineering and microfabrication (Slide 6).
- The deck lists extensive community and government support, including NRC-IRAP and Alberta Innovates (Slide 7).
Executive Summary: The Precision Play in Neuromodulation
Neuraura’s investor deck, dated May 14th, 2019, presents a hardware-centric solution to the limitations of current brain-machine interfaces. The company’s value proposition centers on a massive leap in sensor density and resolution, enabled by microfabrication. By moving from 6mm legacy electrodes to 17-micrometer sensors, Neuraura aims to provide the 'granularity' required for modern AI and machine learning applications in neurology. The deck is structured to move from technical superiority to research validation, concluding with a broad commercialization roadmap that spans both direct sales and high-level licensing.
Slide 1: Title Slide
The deck opens with the company logo and the tagline 'UNLOCKING THE BRAIN.' It is dated May 14th, 2019. The branding is clean and professional, using a purple and blue geometric 'N' logo that evokes both neural networks and high-tech manufacturing.
Slide 2: The Vision Statement
Slide 2 serves as a mission statement: 'Neuraura will improve the lives of billions of people by unlocking the field of neuromodulation with next-generation neuro sensors.' This is a standard 'Big Vision' slide. While 'billions of people' is an ambitious claim, it sets the stage for a platform technology rather than a niche medical device.
Slide 3: Technical Specifications and Validation
This is the 'meat' of the technical pitch. Neuraura compares its electrodes (17 micrometers) to legacy electrodes (6mm). The slide lists five key performance indicators: 350x smaller, 20x spatial resolution, 3x signal resolution, more accurate recording, and safer stimulation. A graph shows a seizure recording, providing visual evidence of the sensor's utility. At the bottom, four icons highlight key milestones: 100% seizure detection in animal trials, secured clinical and research collaborations, MRI compatibility, and the status of their intellectual property (IP transferred, 4 patents in process).
Slide 4: Neuroscience Research Tools (Short-term Revenue)
Slide 4 details the first phase of their business model. The problem identified is 'Poor data quality' and 'Expensive equipment.' The solution is 3x better signal resolution and improved repeatability. The approach is to sell hardware to researchers. The slide lists impressive collaborators, categorized by trial type: In-Vitro (Harvard Medical School), In-Vivo animal (McGovern Institute), and In-Vivo human (UC San Diego, University of Melbourne, University of Calgary). This slide effectively builds credibility by association with world-class institutions.
Slide 5: The Licensing Strategy (Long-term Scale)
Slide 5 shifts focus to the broader market: 'Neuraura’s Sensors in Every Brain Implant.' The problem here is that legacy sensors risk tissue damage and lack the granularity for AI/ML. The strategy is to displace legacy tech by licensing to 'established medical device manufacturers.' The slide lists specific targets, including Medtronic, Boston Scientific, and Abbott. It also mentions co-development with emerging players like Kernel. This demonstrates a clear understanding of the medical device ecosystem, where acquisition or licensing by a 'Big MedTech' player is a common exit or scaling path.
Slide 6: The Team
The team slide presents a 'Strong Multidisciplinary Team.' It features Pierre Wijdenes, PhD (CEO, neuro-engineering expert) and Colin Dalton, PhD (CTO, microfabrication expert). The 'Extended Team' includes business advisors from Zinc Ventures and Panache Ventures, and clinical advisors from the University of Calgary and the Alberta Children’s Hospital. The presence of both technical founders and experienced venture advisors suggests a balanced leadership structure.
Slide 7: Contact and Community Partners
The final slide provides contact information for the CEO, COO (Claire Dixon), and CTO. The bottom half of the slide is crowded with logos of 'community partners,' including government bodies (NRC-IRAP, Government of Canada), accelerators (Creative Destruction Lab, C100), and universities. This high volume of logos serves as 'social proof,' indicating that the company has successfully navigated the Canadian innovation ecosystem and secured non-dilutive support.
What Neuraura Does Well
Technical Differentiation: The comparison on Slide 3 is the strongest part of the deck. By quantifying the size difference (350x) and resolution improvement (20x), they make a compelling case for why their hardware is a generational leap over existing technology.
Strategic Phasing: The deck clearly separates the 'Research Tools' business from the 'Licensing' business. This shows investors a path to early revenue and data collection through research sales, which de-risks the longer-term, higher-hurdle goal of getting into permanent human implants.
Credibility through Association: Listing Harvard, UC San Diego, and Medtronic (even as a target) shows that the founders understand who the power players are in their space and have already made inroads with top-tier academic institutions.
What is Missing from the Deck
The Ask: The most significant omission is the lack of a funding slide. There is no mention of how much money is being raised, the valuation, or the specific milestones the company intends to hit with the next round of capital.
Market Size (TAM): While the vision slide mentions 'billions of people,' the deck lacks a formal Total Addressable Market (TAM) analysis. Investors need to know the dollar value of the research tool market versus the implant licensing market.
Competition: The deck lists 'emerging competitors' as co-development targets (like Kernel), but it does not provide a competitive matrix. It assumes that being '350x smaller' is an uncontested win, without addressing other ways to solve the resolution problem (e.g., software-based signal processing or different sensor modalities).
Unit Economics: There is no information on the cost to manufacture these micro-fabricated sensors or the price point for the research kits. This makes it difficult to evaluate the viability of the 'Research Tools' business model.
Founder Takeaways: Lessons from Neuraura
Quantify Your Advantage: If your product is better, say exactly how much better. Neuraura’s use of '350x smaller' and '20x spatial resolution' is much more effective than saying 'our sensors are significantly smaller and more precise.'
Map the Ecosystem: Slide 5 is a masterclass in identifying where a startup fits into a complex industry. By categorizing companies into 'In-house,' 'Co-development,' and 'Licensing,' the founders show they have a sophisticated view of their path to market.
Leverage Non-Dilutive Proof: The 'Community Partners' slide (Slide 7) is a great way for early-stage deep tech companies to show momentum. Even if you haven't raised a massive Series A, showing support from government grants and prestigious accelerators proves that you have passed multiple levels of professional due diligence.
Frequently asked questions
- What is the primary technical advantage of Neuraura's sensors?
- According to slide 3, the primary advantage is extreme miniaturization and precision. The sensors are 350x smaller than legacy 6mm electrodes, coming in at 17 micrometers. This allows for 20x better spatial resolution and 3x better signal resolution, which the company claims enables safer stimulation and more accurate recording of brain activity, such as seizures.
- How does Neuraura plan to make money in the short term?
- Slide 4 outlines a 'Neuroscience Research Tools' approach. The company plans to sell sensors and hardware directly to researchers. The strategy involves executing research collaborations, converting unpaid pilots to paid ones, and leveraging Key Opinion Leaders (KOLs) to promote the tech through publications. Eventually, they aim to sell through established channel partners.
- Who are the target customers for Neuraura's long-term licensing play?
- Slide 5 identifies several 'Licensing Targets' among established medical device manufacturers. These include industry leaders such as Medtronic, Boston Scientific, Abbott, Neuropace, Nevro, and Ottobock. They also list 'Co-development Targets' like Kernel and GTXmedical, suggesting a broad B2B integration strategy.
- What clinical validation has the company achieved so far?
- As of the 2019 deck, slide 3 notes that Neuraura has achieved 100% seizure detection in animal trials. The technology is also noted as being MRI compatible for safe imaging in humans. Slide 4 lists active in-vivo human research collaborations with the University of Calgary, University of Alberta, and University of Melbourne.
- What is missing from this version of the Neuraura pitch deck?
- The provided slides omit several standard investor requirements. There is no 'Ask' slide detailing how much capital is being raised or the intended use of funds. Furthermore, there are no financial projections, no detailed market size (TAM/SAM/SOM) beyond a vague mention of 'billions of people,' and no specific competitive analysis comparing them to other startups in the neurotech space.
